http://lymeconnection.org/news_publications/meet_the_lyme_disease_experts.html

Meet the Lyme Disease Experts

Interview with Autoimmune Neurologist Elena Frid, M.D.

Dr. Elena Frid is a board-certified neurologist, neurophysiologist, and ILADS member who specializes in the care of children and adults with autoimmune disorders and infectious processes, especially Lyme disease. Inspired by her own children, she has also developed a protective clothing line to keep them safe while playing outdoors. Recently, Lyme Connection newsletter editor Janet Jemmott spoke with her in the New York City office where she is the medical director.

How did you become interested in infections induced autoimmune syndromes?

In my residency and fellowship training program, we were introduced to a number of autoimmune disorders including limbic encephalitis and various types of neuropathies, and this piqued my interest. Then, shortly after I established my private practice, I was exposed to patients who did not fit into a purely psychiatric or a specific neurologic diagnosis. I started working closely with these patients, often learning from them about various workups and treatments they had undergone. Many of them mentioned Lyme disease and brought in articles and talked about organizations such as International Lyme and Associated Diseases Society (ILADS).

After I attended a few conferences it became clear to me that there is an association between infections and neuro-developmental, neuropsychiatric, and in some instances, neurodegenerative conditions. It was clear that in many of the patients I was seeing, infections, inflammation, and autoimmune processes were the trigger to their neurologic syndrome and clinical presentation.

If a patient comes in to see you and you suspect they have an infection or multiple infections that have induced some kind of autoimmune syndrome, Lupus or MS or Chronic Fatigue Syndrome – how do you determine, one, that they have an ongoing infection and if they have an autoimmune syndrome?

I rely on detailed history taking, physical exam findings, extensive blood testing, which may include some specialty labs, imaging studies such as MRIs and brain SPECT, and other diagnostic tools including Electroencephalogram (EEG), Nerve conduction studies/Electromyography (NCV/EMG), Lumbar puncture (LP), neurocognitive assessment and others depending on clinical presentation.

So the testing provides you with the background. The testing, say for Borrelia, is at this point still inconclusive. So, is it a matter of taking the lab work results and adding the clinical picture to it – that is, what you can get from the patient’s history?

That’s exactly right. To this day, neurology is one of the few subspecialties in medicine that still very heavily relies on clinical exam and history taking. Therefore, a lot of the tools we have, such as an EEG, MRI, or a nerve conduction study are used as an extension of one’s clinical exam.

So if a patient walks into your office and you know they had tick-borne disease in the past and it looks like they fell through the cracks and at this point the TBD is disseminated through their body and they’re having all kinds of symptoms, how do you go about treating them? I remember that you said at the May Lyme Connection Patient Conference that “You have to treat all the things at once.” How do you do that?

I start with extensive blood work, including checking for infectious, inflammatory, and autoimmune processes. To test for certain infections and autoimmune disorders I often use specialty labs and other neurologic testing. Once we obtain those results, I have a better understanding of the pathophysiology of the patient’s clinical presentation. I start treating their infections and when appropriate, their autoimmune disorders as well.

Okay. So can an autoimmune process be halted or reversed even?

Yes.

Does that require treatment with IVIG?

Not always. In some cases, the autoimmune response will subside by treating the underlying disease process, such as an infection. It really depends on the person’s genetic makeup and genetic predisposition to autoimmune disorders. Many patients will need three to six months to respond to treatment. Beyond that, rechecking their clinical status, infections, and autoimmune process is appropriate, and perhaps, changing their treatment strategy.

Say someone’s diagnosed with multiple sclerosis, does that mean that the disease process has really advanced; are you able to back up from there?

So, the question is, is an MS type presentation of Lyme disease reversible?

Right.

It depends on the patient. It depends on their clinical exam. Does the patient have any good days? Do they have any time in the day or the week when they feel close to 100 percent normal? If the answer to that is yes, it speaks to the reversibility of the disease process. That’s an important piece of history that I always talk about with patients.

Can you explain how an infection triggers a neurological process, say encephalitis? 

In my opinion, there are three steps. One, is the direct extension of the infection into the nervous system, because of a break in the blood-brain barrier. Second, there is an inflammatory response. And third, there is an autoimmune phenomenon, which is when your own body is creating antibodies against itself due to molecular mimicry. Think about where most of our DNA came from. Parts of our DNA are similar to infectious agents that we come in contact with regularly, so they’ve been incorporated into our DNA. When someone gets exposed to an infection that already makes up a significant portion of their DNA, that infection can trigger an autoimmune response in some patients.

Can tick-borne infections other than Borrelia – say Babesia, Anaplasma, Ehrlichia – can they also infect the brain in a similar way?

Absolutely. Not only that. We know about Streptococcal infections causing neurologic issues. For example:  Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), Pediatric Autoimmune Neuropsychiatric Disorder (PANS) or Sydenham’s Chorea. Syphilis, caused by a spirochete similar to Borrelia burgdorfi, also causes a lot of neurologic manifestations.

Changing topics for a moment. The Washington Post published an article in June that was a one-sided and incomplete story on the damage IV antibiotics cause – how do Lyme patients push back against this?

I think Lyme patients can help educate the medical community. When a patient is successfully treated, they should go back to their physicians and let them know what it took to get back on their feet. Those who are continuing to struggle and have physicians who are willing to explore various diagnoses can bring them medical literature and articles like this one or encourage their doctor to attend conference such as the annual ILADS symposium.

There are doctors who are saying: You got a tick bite; I’m going to give you a single dose of 200 mg. doxycycline. That will be prophylaxis. And you’ll be fine.  How do we arm people with facts so they can say, that’s not enough.

According to ILADS guidelines, a person who has had a tick bite – especially in an endemic area – should be treated for three to six weeks. If they continue to exhibit symptoms, they can be treated longer.

In certain parts of Connecticut for example, when the tick population was monitored, up to 90% of ticks carried tick-borne diseases that could be transmitted to you or your pet. With that being said, people who work or play outdoors need to realize the threat of Lyme disease and dress appropriately. Wear long-sleeve shirts, socks, light-colored clothing and closed-toe shoes. In fact, I’ve created a product to protect my own kids, DrFridKidswear, that is pretreated with insect repellent. This is the most effective way to protect your kids against bites from disease carrying insects. You should also be aware of the protocol if you spot a tick on your body, but realize that up to 50% of people never detect a tick bite prior to the onset of their symptoms.

The current literature says to be prone to Lyme disease, a tick has to be attached to an individual for 48 to 72 hours — that is incorrect. Again, those who have detected a tick bite, especially in endemic areas, should begin a proper course of treatment without waiting for specific symptoms like a bulls-eye rash.

Recently a friend had a tick bite, so she called the doctor who said he would give her a single dose of doxycycline. But when she told him it was three days after the bite he would not treat her since she didn’t have acute symptoms.

Incubation period for Borrelia burgdorferi bacteria is typically three to thirty days. Therefore, symptom onset can be delayed and often waxes and wanes. Having said that, both patients and physicians should be vigilant of vague or odd symptomatology that continues to recur. Now-a-days, especially in endemic areas, tick bites should be treated.

Which is certainly worth the cost if you look at the long course of Lyme disease.

Completely agree!

What happens if you have a repeat exposure?

In my clinical practice, I find that those patients with complicated presentations of neurologic Lyme are those patients who have a long history of re-exposure. Typically it’s not just the one tick bite that causes these daunting symptoms.

In the case of someone who, over 30 years, has had half-a-dozen tick bites with known reactions, sometimes has been treated, sometimes not, but now has a multitude of symptoms because over time it has progressed. How do you treat a patient like that?

The same way.

Because there are so many co-infections, can you always identify them?

No. But that’s why you repeat testing regularly, every three to six months or with any significant change in patient’s clinical presentation. If a patient is doing extremely well, that’s your marker to take them off antibiotics but you want to make sure their blood work is looking good. If a patient’s doing poorly, you want to see if there are co-infections that weren’t identified the first time, potentially because their immune system wasn’t strong enough to mount an immune response against them. When you start treating them and they’re into their treatment protocol, then their immune system is stronger and you can see more of the antibodies that are developing, and that can steer you in the direction of how to treat them. Another possibility is that they’ve acquired another illness, either another tick bite or another common infection, like a respiratory infection that’s not clearing, that needs to be addressed as well.

Do you treat with eastern as well as western modalities?

I think there’s a role for eastern modalities; I don’t think it’s for everyone. I honestly think that the time to worry about your health is when you’re healthy. Healthy eating, supplementing with herbs, and healthy lifestyle can be very good for everybody. I don’t necessarily expect that just because someone changes their diet they can be cured of symptoms of ALS, MS, or severe neurological Lyme symptoms.

Do you have any words of advice for the people in the Lyme community who are struggling, since the testing is not always adequate and the medical community is not always on-board for accepting and treating chronic Lyme. What do people do?

Educating oneself is key. Knowledge is power. There is more interest now in trying to understand Lyme disease and autoimmune disorders. More and more information is coming out about complex presentations and the need for better testing and treatment. Change is coming! For those who are in the midst of a struggle and are not getting better – explore the autoimmune component of the disease pathophysiology, as it may be the key to getting you better.

So do you see the medical community as on the edge, teetering into acceptance?

That’s an overstatement. I think we’ve made some baby steps in the right direction. The Lyme community’s outcries are being heard and there are some big name institutions that are sponsoring research, as well as not-for-profit organizations such as ProjectLyme and the BLAST program that are raising awareness and educating on prevention. Also, Global Lyme Alliance is working to fund research for better testing and treatment options. Lymedisease.org is collecting big data on the Lyme community and that will also help propel Lyme research forward.

For more information about Dr. Frid, check her website.
You can also follow her on Instagram @drelenafrid, Facebook @drelenafrid, Twitter @ElenaFridMD, and YouTube – Lyme Talk with Dr. Frid. Her insect repellent clothing line for children is DrFrid Kidswear.

Read what all the experts had to say….

The interviews included on this website are informational only and not intended as medical advice. They express only the opinions of the subjects being interviewed and are not necessarily those of Lyme Connection or the Town of Ridgefield.  Lyme Connection makes no express or implied warranties as to the efficacy or safety of any treatment in its articles and disclaim all liability for any use of any such treatment. Please consult your physician regarding treatments.

Lyme Connection has no affiliation with any of the professionals interviewed and cannot assist with appointments or recommendations. Please do not contact Lyme me Connection to make appointments with treating physicians. All physicians and researchers interviewed should be contacted directly with your questions and requests. Thank you.

https://vimeo.com/95647143  Approx. 53 Min

LYME DISEASE A SILENT EPIDEMIC PRODUCED BY FRANCE 5 PUBLIC NETWORK AND GRAND ANGLE DIRECTED BY CHANTAL PERRIN

 

Cat scratch disease: U.S. clinicians’ experience and knowledge.

Nelson CA, et al. Zoonoses Public Health. 2017.  Epub ahead of print

Authors

Nelson CA1, Moore AR2, Perea AE1, Mead PS1.

Author information

  • 1Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.
  • 2University of Virginia School of Medicine, Charlottesville, VA, USA.

https://www.ncbi.nlm.nih.gov/m/pubmed/28707827/

Abstract

Cat scratch disease (CSD) is a zoonotic infection caused primarily by the bacterium Bartonella henselae. An estimated 12,000 outpatients and 500 inpatients are diagnosed with CSD annually, yet little is known regarding clinician experience with and treatment of CSD in the United States. Questions assessing clinical burden, treatment and prevention of CSD were posed to 3,011 primary care providers (family practitioners, internists, paediatricians and nurse practitioners) during 2014-2015 as part of the annual nationwide DocStyles survey.

Among the clinicians surveyed, 37.2% indicated that they had diagnosed at least one patient with CSD in the prior year. Clinicians in the Pacific and Southern regions were more likely to have diagnosed CSD, as were clinicians who saw paediatric patients, regardless of specialty.

When presented with a question regarding treatment of uncomplicated CSD, only 12.5% of clinicians chose the recommended treatment option of analgesics and monitoring, while 71.4% selected antibiotics and 13.4% selected lymph node aspiration. In a scenario concerning CSD prevention in immunosuppressed patients, 80.6% of clinicians chose some form of precaution, but less than one-third chose the recommended option of counseling patients to treat their cats for fleas and avoid rough play with their cats.

Results from this study indicate that a substantial proportion of U.S. clinicians have diagnosed CSD within the past year. Although published guidelines exist for treatment and prevention of CSD, these findings suggest that knowledge gaps remain. Therefore, targeted educational efforts about CSD may benefit primary care providers.

Improved serodiagnostic performance for Lyme disease by use of two recombinant proteins in ELISA as compared to standardized two tier testing

Bradshaw GL, Thueson RK, Uriona TJ.

Journal of Clinical Microbiology, online first, 2017 Aug 2.

https://doi.org/10.1128/JCM.01004-17

Abstract

The most reliable test method for the serological confirmation of Lyme Disease (LD) is a 2-tiered method recommended by the CDC in 1995. The first-tier test is a low specificity ELISA test and the second-tier tests are higher specificity IgG and IgM Western blots. This study describes the selection of two Borrelia burgdorferi-recombinant proteins and evaluation of their performance in a simple 1-tier test for the serological confirmation of LD.

These two proteins were generated from
(a) the full length dbpA gene combined with the invariable region 6 of the VlsE gene (dbpA/C6) and
(b) the full length OspC gene.

The expressed dbpA/C6 and the OspC proteins were useful in detecting anti-Borrelia IgG and IgM antibodies, respectively. A blind study was conducted on a well-characterized panel of 279 human sera from the CDC comparing ELISA tests using these two recombinant antigens with the 2-tiered test method. The two methods (dbpA/C6-OspC vs 2-tiered) compared equivalently in identifying sera from negative control subjects (99% vs 100% specificity, respectively) and in detecting stage II & III LD patient sera (100% vs 100% sensitivity). However, the dbpA/C6-OspC ELISA test was markedly better (80% vs 63%) than the 2-tiered test method in detecting anti-Borrelia antibodies in stage I LD patients.

The finding suggest that these antigens could be used in a simple 1-tier ELISA assay that is faster to perform, easier to interpret, and less expensive than the 2-tiered test method, and which is better at detecting Borrelia specific antibodies in patient sera with stage I LD.

More on testing:

https://madisonarealymesupportgroup.com/2017/04/12/comparing-lyme-testing-with-hiv-testing/

38_sensitive316x316   01_test_petri316x31625_antibody316x316

https://www.lymedisease.org/lyme-basics/lyme-disease/diagnosis/  Testing explained and interpreted.

 

 

 

 

Cases of transfusion-transmitted babesiosis occurring in nonendemic areas: a diagnostic dilemma
LeBel, D. P., Moritz, E. D., O’Brien, J. J., Lazarchick, J., Tormos, L. M., Duong, A., Fontaine, M. J., Squires, J. E. and Stramer, S. L.
Transfusion, online first August 7, 2017.

https://doi.org/10.1111/trf.14246

Abstract

BACKGROUND
Transfusion-transmitted babesiosis (TTB) has been rapidly increasing in incidence since the beginning of the 21st century. Asymptomatic individuals with Babesia infection are able to donate blood in the United States because of the lack of specific blood donation testing. Blood products collected in Babesia-endemic areas are distributed nationally; thus, clinicians in nonendemic states may fail to include babesiosis in the differential diagnosis of a patient who had a recent transfusion history and a fever of unknown origin.

STUDY DESIGN AND METHODS
We report the details of two cases of clinical transfusion-transmitted babesiosis and one asymptomatic infection identified in red blood cell recipients in two nonendemic states (South Carolina and Maryland), which, when combined with three recent additional cases in nonendemic states, totals six recipient infections in three nonendemic states.

RESULTS
Delayed diagnosis of transfusion-transmitted babesiosis places patients at risk for increased morbidity and mortality and may result in clinical mismanagement or unnecessary treatments. A peripheral blood smear should be reviewed in any patient with a recent transfusion and a fever of unknown origin. Prompt communication of the diagnosis among physicians is key to ensuring that patients with transfusion-transmitted babesiosis are treated expeditiously, and a transfusion service investigation is necessary to identify additional recipients from the same donor.

CONCLUSION
TTB is appearing in traditionally nonendemic states because of blood product distribution patterns. Clinicians should include TTB on the differential diagnosis in any patient presenting who had a recent transfusion history and a fever of unknown origin, regardless of where the transfusion took place.

More on Babesia:  https://madisonarealymesupportgroup.com/2016/01/16/babesia-treatment/

https://madisonarealymesupportgroup.com/2016/11/19/seroprevalence-of-babesia-in-individuals-with-ld/

https://madisonarealymesupportgroup.com/2016/10/31/the-gift-that-keeps-giving-wisconsin-organ-donor-gives-babesiosis-to-two-recipients/